JP3301100008
JP3301100008
KOBAYASHI PHARMACEUTICALS
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±25.3% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.2x).
Beta (Market Relation)
0.2x
DefensiveVolatility (5Y p.a.)
25.3% p.a.
5-Year HorizonMax Drawdown (5Y)
-53.1%
5-Year HorizonSharpe Ratio
-0.25
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +37.4% |
| 3 Years | 26.6% | -29.8% | -0 | +2.5% |
| 5 Years | 25.3% | -53.1% | -0.25 | -3.7% |
| 10 Years | 26.8% | -62.1% | 0.02 | +3.1% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 329.7 (Elevated multiple compression risk)
Historical Stress Test: Maximum peak-to-trough drawdown of -62.1% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
4 ISS Score: 4 / 10
Audit Risk
1 ISS Score: 1 / 10
Board Risk
3 ISS Score: 3 / 10
Short Ratio
-